Ad
related to: glaucoma gene therapy clinical trials in california state hospital grave markers
Search results
Results from the WOW.Com Content Network
Retinal gene therapy holds a promise in treating different forms of non-inherited and inherited blindness. In 2008, three independent research groups reported that patients with the rare genetic retinal disease Leber's congenital amaurosis had been successfully treated using gene therapy with adeno-associated virus (AAV).
The California Institute for Regenerative Medicine (CIRM) is a state agency that supports research and education in the fields of stem cell and gene therapiesIt was created in 2004 after 59% of California voters approved California Proposition 71: the Research and Cures Initiative, [1] which allocated $3 billion to fund stem cell research in California.
The first retinal gene therapy to be approved by the FDA was Voretigene neparvovec in 2017, which treats Leber's congenital amaurosis, a genetic disorder that can lead to blindness. These treatments also use subretinal injections of AAV vector and are therefore foundational to research in gene therapy for color blindness. [2] [3]
The Center for Cell and Gene Therapy conducts research into numerous diseases, including but not limited to pediatric cancers, [5] [6] diabetes, [7] HIV, glioma [8] and cardiovascular disease. The center has laboratory space in both Baylor College of Medicine and Texas Children's Hospital, and clinical units in Texas Children's and Methodist ...
City of Hope is a private, non-profit clinical research center, hospital and graduate school located in Duarte, California, United States.The center's main campus resides on 110 acres (45 ha) of land adjacent to the boundaries of Duarte and Irwindale, with a network of clinical practice locations throughout Southern California, satellite offices in Monrovia and Irwindale, and regional ...
Alipogene tiparvovec (Glybera): AAV-based treatment for lipoprotein lipase deficiency (no longer commercially available); Axicabtagene ciloleucel (Yescarta): treatment for large B-cell lymphoma [1]
Current Gene Therapy is a peer-reviewed medical journal published by Bentham Science Publishers.The editor-in-chief is Liang Cheng (Harbin Medical University Harbin, China). ). The focus of this journal is pre-clinical or clinical research on gene the
Human clinical trials are underway at GenSight Biologics (ClinicalTrials.gov # NCT02064569) and the University of Miami (ClinicalTrials.gov # NCT02161380) to examine the safety and efficacy of mitochondrial gene therapy in LHON. In these trials, participants affected by LHON with the G11778A mutation will have a virus expressing the functional ...
Ad
related to: glaucoma gene therapy clinical trials in california state hospital grave markers